{
  "claim_id": "claim_001",
  "claim": "Flublok contains 3x the hemagglutinin (HA) antigen content of standard-dose flu vaccines, which has been linked to greater immunogenicity vs standard-dose flu vaccines.",
  "document": "Zimmerman_et_al.__2023_",
  "additional_evidence_check": {
    "checked_for_more": true,
    "found_additional": true,
    "additional_count": 2
  },
  "completeness_stats": {
    "existing_evidence": 5,
    "new_evidence_found": 2,
    "total_evidence": 7
  },
  "combined_evidence": [
    {
      "id": 1,
      "quote": "Standard Dose Fluzone and FlucelVax. HD-IIV4 was High Dose Fluzone, RIV4 was Flublok and Adj-IV was FluAd.",
      "relevance_explanation": "This quote explicitly identifies RIV4 as Flublok, which is necessary to connect subsequent statements about RIV4 to the specific product Flublok, supporting the claim about its antigen content and immunogenicity."
    },
    {
      "id": 2,
      "quote": "Two large studies have explored rVE of recombinant quadrivalent influenza vaccine (RIV4). The Medicare beneficiaries study [10] using retrospective data as described above, reported significant rVE of RIV4 vs. SD-IIV4) against influenza related hospital encounters. Secondly, a randomized controlled trial (RCT) found significant rVE of RIV4 compared with SD-IIV4 among adults 50 years old, but not for adults 65 years old [11].",
      "relevance_explanation": "This quote provides direct evidence that RIV4 (Flublok) has greater effectiveness (relative vaccine effectiveness, rVE) compared to standard-dose influenza vaccines (SD-IIV4), supporting the claim that higher antigen content is linked to greater immunogenicity."
    },
    {
      "id": 3,
      "quote": "Conclusions: Overall adults, both RIV4 and SD-IIV4 were effective against influenza hospitalization, RIV4 providing better protection compared with SD-IIV4 overall, for females, younger adults, and those with no high risk conditions.",
      "relevance_explanation": "This quote states that RIV4 (Flublok) provided better protection than SD-IIV4, directly supporting the claim that the higher antigen content in Flublok is associated with greater immunogenicity and effectiveness."
    },
    {
      "id": 4,
      "quote": "Relative vaccine effectiveness (rVE) of recombinant quadrivalent influenza vaccine (RIV4) and RIV4 + high dose quadrivalent influenza vaccine (HD-IIV4) + adjuvanted influenza vaccine (Adj-IV) vs. standard dose quadrivalent influenza vaccine (SD-IIV4) by age group, % (95% CI).",
      "relevance_explanation": "This quote introduces data comparing the effectiveness of RIV4 (Flublok) to standard-dose vaccines, which is relevant to the claim about greater immunogenicity due to higher antigen content."
    },
    {
      "id": 5,
      "quote": "Because it is not subject to mutations to the A (H3N2) glycosylation binding site that reduce the effectiveness of egg based vaccines.",
      "relevance_explanation": "This quote highlights a mechanistic advantage of RIV4 (Flublok) over standard-dose, egg-based vaccines, supporting the claim that Flublok's formulation (including higher antigen content) is linked to greater immunogenicity."
    },
    {
      "id": "comp_1",
      "quote": "RIV4: Flublok. c SD-IIV4: Afluria, Fluarix, FluLaval, Standard Dose Fluzone and FlucelVax.",
      "relevance_explanation": "This quote explicitly identifies RIV4 as Flublok and SD-IIV4 as standard-dose flu vaccines, establishing the products being compared in the context of the claim about antigen content and immunogenicity.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    },
    {
      "id": "comp_2",
      "quote": "RIV4: Flublok; HD IIV4: High dose Fluzone; Adj IV: FluAd",
      "relevance_explanation": "This quote clarifies that RIV4 refers to Flublok, which is necessary to connect the discussion of recombinant vaccine effectiveness and antigen content to the specific product named in the claim.",
      "source": "completeness_check",
      "metadata": {
        "extraction_round": 2,
        "targeted_aspect": "general"
      }
    }
  ],
  "completeness_assessment": {
    "missing_aspects": []
  },
  "model_used": "gpt-4.1"
}